Astrogliosis is delayed in type 1 interleukin-1 receptor-null mice following a penetrating brain injury

Journal of Neuroinflammation

Volumn 3, Issue , 2006, Pages

  Lin, Hsiao Wen ^a   Basu, Anirban ^b   Druckman, Charles ^c   Cicchese, Michael ^c   Krady, J Kyle ^c   Levison, Steven W ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NATIONAL BRAIN RESEARCH CENTRE   (India)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE AMMONIA LIGASE; GLUTAMATE TRANSPORTER; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PROTEIN S100B; PROTEINASE ACTIVATED RECEPTOR 1; PROTEOCHONDROITIN SULFATE; TENASCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN INJURY; CELL ACTIVATION; CONTROLLED STUDY; MACROGLIA; MACROPHAGE; MALE; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; PENETRATING TRAUMA; PROTEIN INDUCTION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; STAB WOUND; WILD TYPE;

EID: 33747195021     PISSN: 17422094     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-3-15     Document Type: Article

References (79)

1. Allan SM, Rothwell NJ: Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2(10):734-744.
2. Minami M, Kuraishi Y, Yabuuchi K, Yamazaki A, Satoh M: Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia. J Neurochem 1992, 58:390-392.
3. Legos JJ, Whitmore RG, Erhardt JA, Parsons AA, Tuma RF, Barone FC: Quantitative changes in interleukin proteins following focal stroke in the rat. Neuroscience Letters 2000, 282(3):189-192.
4. Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, Shimizu-Sasamata M, Yuan J, Moskowitz MA: Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci U S A 1997, 94:2007-2012.
5. Friedlander RM, Gagliardini V, Hara H, Fink KB, Li W, MacDonald G, Fishman MC, Greenberg AH, Moskowitz MA, Yuan J: Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. Journal of Experimental Medicine 1997, 185:933-940.
6. Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ: Role of IL-1 alpha and IL-1 beta in ischemic brain damage. J Neurosci 2001, 21(15):5528-5534.
7. Schielke GP, Yang GY, Shivers BD, Betz AL: Reduced ischemic brain injury in interleukin-1β converting enzyme-deficient mice. Journal of Cerebral Blood Flow & Metabolism 1998, 18:180-185.
8. Loddick SA, Rothwell NJ: Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. Journal of cerebral Blood Flow & Metabolism 1996, 16(5):932-940.
9. Relton JK, Rothwell NJ: Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992, 29(2):243-246.
10. Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K: Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995, 26:676-681.
11. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C: Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989, 86(19):7611-7615.
12. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer's disease. Neurobiology of Aging 2000, 21(3):383-421.
13. Hofman FM, von Hanwehr RI, Dinarello CA, Mizel SB, Hinton D, Merrill JE: Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. Journal of Immunology 1986, 136:3239-3245.
14. Deckert-Schluter M, Schluter D, Schwendemann G: Evaluation of IL-2, sIL2R, IL-6, TNF-alpha, and IL-1 beta levels in serum and CSF of patients with optic neuritis. Journal of Neurological Sciences 1992, 113(1):50-54.
15. McGuinness MC, Powers JM, Bias WB, Schmeckpeper BJ, Segal AH, Gowda VC, Wesselingh SL, Berger J, Griffin DE, Smith KD: Human Leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. Journal of Neuroimmunology 1997, 75:174-182.
16. Eriksson C, Van Dam AM, Lucassen PJ, Bol JG, Winblad B, Schultzberg M: Immunohistochemical localization of interleukin-1beta, interleukin-1 receptor antagonist and interleukin-1beta converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid. Neuroscience 1999, 93(3):915-930.
17. Rothwell NJ, Luheshi GN: Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 2000, 23(12):618-625.
18. Sparacio SM, Zhang Y, Vilcek J, Benveniste EN: Cytokine regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-kappaB-like nuclear protein. Journal of Neuroimmunology 1992, 39:231-242.
19. Norris JG, Tang LP, Sparacio SM, Benveniste EN: Signal transduction pathways mediating astrocyte IL-6 induction by IL-1beta and tumor necrosis factor-alpha. Journal of Immunology 1994, 152:841-850.
20. Chung IY, Benveniste EN: Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol 1990, 144(8):2999-3007.
21. Aloisi F, Care A, Borsellino G, Gallo P, Rosa S, Bassani A, Cabibbo A, Testa U, Levi G, Peschle C: Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. Journal of Immunology 1992, 149:2358-2366.
22. Araujo DM, Cotman CW: Basic FGF in astroglial, microglial, and neuronal cultures: characterization of binding sites and modulation of release by lymphokines and trophic factors. J Neurosci 1992, 12:1668-1678.
23. da Cunha A, Vitkovic L: Transforming growth factor-beta 1 (TGF-beta 1) expression and regulation in rat cortical astrocytes. J Neuroimmunol 1992, 36(2-3):157-169.
24. Herx LM, Rivest S, Yong VW: Central nervous system-initiated inflammation and neurotrophism in trauma: IL-1 beta is required for the production of ciliary neurotrophic factor. J Immunol 2000, 165(4):2232-2239.
25. Gadient RA, Cron KC, Otten U: Interleukin-1 beta and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes. Neurosci Lett 1990, 117:335-340.
26. Bandtlow CE, Meyer M, Lindholm D, Spranger M, Heumann R, Thoenen H: Regional and cellular codistribution of interleukin 1 beta and nerve growth factor mRNA in the adult rat brain: possible relationship to the regulation of nerve growth factor synthesis. J Cell Biol 1990, 111(4):1701-1711.
27. DeKosky ST, Goss JR, Miller PD, Styren SD, Kochanek PM, Marion D: Upregulation of nerve growth factor following cortical trauma. Experimental Neurology 1994, 130(2):173-177.
28. Friedman WJ, Thakur S, Seidman L, Rabson AB: Regulation of nerve growth factor mRNA by interleukin-1 in rat hippocampal astrocytes is mediated by NFkappaB. J Biol Chem 1996, 271(49):31115-31120.
29. Mason JL, Suzuki K, Chaplin DD, Matsushima GK: Interleukin-1 beta promotes repair of the CNS. Journal of Neuroscience 2001, 21(18):7046-7052.
30. Albrecht PJ, Dahl JP, Stoltzfus OK, Levenson R, Levison SW: Ciliary Neurotrophic Factor Activates Spinal Cord Astrocytes, Stimulating their Production and Release of FGF-2, to increase Motor Neuron Survival. Experimental Neurology 2002, 173:46-62.
31. Basu A, Krady JK, O'Malley M, Styren SD, DeKosky ST, Levison SW: The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J Neurosci 2002, 22(14):6071-6082.
32. Basu A, Lazovic J, Krady JK, Mauger DT, Rothstein RP, Smith MB, Levison SW: Interleukin-1 and the interleukin-1 type I receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury. J Cereb Blood Flow Metab 2005, 25(1):17-29.
33. Lazovic J, Basu A, Lin HW, Rothstein RP, Krady JK, Smith MB, Levison SW: Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type I receptor-deficient mice conferring neuroprotection. Stroke 2005, 36(10):2226-2231.
34. Kuhlow CJ, Krady JK, Basu A, Levison SW: Astrocytic ceruloplasmin expression, which is induced by IL-1beta and by traumatic brain injury, increases in the absence of the IL-1 type I receptor. Glia 2003, 44(1):76-84.
35. Nawashiro H, Brenner M, Fukui S, Shima K, Hallenbeck JM: High susceptibility to cerebral ischemia in GFAP-null mice. J Cereb Blood Flow Metab 2000, 20(7):1040-1044.
36. Nawashiro H, Messing A, Azzam N, Brenner M: Mice lacking GFAP are hypersensitive to traumatic cerebrospinal injury. Neuroreport 1998, 9(8):1691-1696.
37. Swanson RA, Ying W, Kauppinen TM: Astrocyte influences on ischemic neuronal death. Curr Mol Med 2004, 4(2):193-205.
38. Donato R: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003, 60(6):540-551.
39. Winningham-Major F, Staecker JL, Barger SW, Coats S, Van Eldik LJ: Neurite extension and neuronal survival activities of recombinant S100 beta proteins that differ in the content and position of cysteine residues. J Cell Biol 1989, 109(6 Pt 1):3063-3071.
40. Donato R: S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001, 33(7):637-668.
41. Nicole O, Goldshmidt A, Hamill CE, Sorensen SD, Sastre A, Lyuboslavsky P, Hepler JR, McKeon RJ, Traynelis SF: Activation of protease-activated receptor-1 triggers astrogliosis after brain injury. J Neurosci 2005, 25(17):4319-4329.
42. Levison SW, Ducceschi MH, Young GM, Wood TL: Acute exposure to CNTF in vivo induces multiple components of reactive gliosis. Exp Neurol 1996, 141(2):256-268.
43. Henderson CE, Bloch-Gallego E, Camu W: Purified Embryonic Motoneurons. In Neural Cell Culture: a practical approach Edited by: Cohen, Wilkin. London, Oxford University Press; 1994.
44. O'Callaghan JP: Quantification of glial fibrillary acidic protein: comparison of slot-immunobinding assays with a novel sandwich ELISA. Neurotoxicol Teratol 1991, 13(3):275-281.
45. Herx LM, Yong VW: Interleukin-1 beta is required for the early evolution of reactive astrogliosis following CNS lesion. J Neuropathol Exp Neurol 2001, 60(10):961-971.
46. Xi G, Reiser G, Keep RF: The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J Neurochem 2003, 84(1):3-9.
47. Bauer J, Berkenbosch F, van Dam AM, Dijkstra CD: Demonstration of interleukin-1 beta in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level. J Neuroimmunol 1993, 48:13-21.
48. Martin D, Chinookoswong N, Miller G: The interleukin-1 receptor antagonist (rhIL-Ira) protects against cerebral infarction in a rat model of hypoxia-ischemia. Experimental neurology 1994, 130:362-367.
49. Hedtjarn M, Leverin AL, Eriksson K, Blomgren K, Mallard C, Hagberg H: Interleukin-18 involvement in hypoxic-ischemic brain injury. J Neurosci 2002, 22(14):5910-5919.
50. Hartung HP, Schaefer B, Heininger K, Toyka KV: Recombinant interleukin-1Beta stimulates eicosanoid production in rat primary culture astrocytes. Brain Research 1989, 489:113-119.
51. Benveniste EN, Sparacio SM, Norris JG, Grenett HE, Fuller GM: Induction and regulation of interleukin-6 gene expression in rat astrocytes. Journal of Neuroimmunology 1990, 30:201-212.
52. Basu A, Krady JK, Levison SW: Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 2004, 78(2):151-156.
53. Lee KR, Colon GP, Betz AL, Keep RF, Kim S, Hoff JT: Edema from intracerebral hemorrhage: the role of thrombin. J Neurosurg 1996, 84(1):91-96.
54. Nishino A, Suzuki M, Ohtani H, Motohashi O, Umezawa K, Nagura H, Yoshimoto T: Thrombin may contribute to the pathophysiology of central nervous system injury. J Neurotrauma 1993, 10(2):167-179.
55. Lee MT, Nardi MA, Hadzi-Nesic J, Karpatkin M: Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1 1/2-year-old girl: report of a case and review of the literature. Am J Hematol 1996, 51(4):307-314.
56. Vaughan PJ, Pike CJ, Cotman CW, Cunningham DD: Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J Neurosci 1995, 15(7 Pt 2):5389-5401.
57. Striggow F, Riek M, Breder J, Henrich-Noack P, Reymann KG, Reiser G: The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. Proc Natl Acad Sci U S A 2000, 97(5):2264-2269.
58. Boven LA, Vergnolle N, Henry SD, Silva C, Imai Y, Holden J, Warren K, Hollenberg MD, Power C: Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J Immunol 2003, 170(5):2638-2646.
59. Colognato R, Slupsky JR, Jendrach M, Burysek L, Syrovets T, Simmet T: Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 2003, 102(7):2645-2652.
60. Shinohara T, Suzuki K, Takada K, Okada M, Ohsuzu F: Regulation of proteinase-activated receptor 1 by inflammatory mediators in human vascular endothelial cells. Cytokine 2002, 19(2):66-75.
61. McKeon RJ, Schreiber RC, Rudge JS, Silver J: Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J Neurosci 1991, 11(11):3398-3411.
62. Davies CA, Loddick SA, Toulmond S, Stroemer RP, Hunt J, Rothwell NJ: The progression and topographic distribution of interleukin-1 beta expression after permanent middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1999, 19(1):87-98.
63. Bovolenta P, Wandosell F, Nieto-Sampedro M: CNS glial scar tissue: a source of molecules which inhibit central neurite outgrowth. Prog Brain Res 1992, 94:367-379.
64. Herndon ME, Lander AD: A diverse set of developmentally regulated proteoglycans is expressed in the rat central nervous system. Neuron 1990, 4(6):949-961.
65. Dou CL, Levine JM: Inhibition of neurite growth by the NG2 chondroitin sulfate proteoglycan. J Neurosci 1994, 14(12):7616-7628.
66. McKeon RJ, Hoke A, Silver J: Injury-induced proteoglycans inhibit the potential for laminin-mediated axon growth on astrocytic scars. Exp Neurol 1995, 136(1):32-43.
67. Yamada T, Tsubouchi H, Daikuhara Y, Prat M, Comoglio PM, McGeer PL, McGeer EG: Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (c-MET) in human brain tissues. Brain Res 1994, 637(1-2):308-312.
68. Maeda N, Hamanaka H, Oohira A, Noda M: Purification, characterization and developmental expression of a brain-specific chondroitin sulfate proteoglycan, 6B4 proteoglycan/phosphacan. Neuroscience 1995, 67(1):23-35.
69. Meyer-Puttlitz B, Junker E, Margolis RU, Margolis RK: Chondroitin sulfate proteoglycans in the developing central nervous system. II. Immunocytochemical localization of neurocan and phosphacan. J Comp Neurol 1996, 366(1):44-54.
70. Nishiyama A, Watanabe M, Yang Z, Bu J: Identity, distribution, and development of polydendrocytes: NG2-expressing glial cells. J Neurocytol 2002, 31(6-7):437-455.
71. Stallcup WB: The NG2 antigen, a putative lineage marker: immunofluorescent localization in primary cultures of rat brain. Dev Biol 1981, 83(1):154-165.
72. Levine JM: Increased expression of the NG2 chondroitin-sulfate proteoglycan after brain injury. J Neurosci 1994, 14(8):4716-4730.
73. Engel U, Wolswijk G: Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells derived from adult rat spinal cord: in vitro characteristics and response to PDGF, bFGF and NT-3. Glia 1996, 16(1):16-26.
74. Oohira A, Matsui F, Watanabe E, Kushima Y, Maeda N: Developmentally regulated expression of a brain specific species of chondroitin sulfate proteoglycan, neurocan, identified with a monoclonal antibody IG2 in the rat cerebrum. Neuroscience 1994, 60(1):145-157.
75. Smith GM, Strunz C: Growth factor and cytokine regulation of chondroitin sulfate proteoglycans by astrocytes. Glia 2005, 52(3):209-218.
76. Krum JM, Phillips TM, Rosenstein JM: Changes in astroglial GLT-1 expression after neural transplantation or stab wounds. Exp Neurol 2002, 174(2):137-149.
77. Eng DL, Lee YL, Lal PG: Expression of glutamate uptake transporters after dibutyryl cyclic AMP differentiation and traumatic injury in cultured astrocytes. Brain Res 1997, 778(1):215-221.
78. Faden AI, Demediuk P, Panter SS, Vink R: The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989, 244(4906):798-800.
79. Basu A, Krady JK, Enterline JR, Levison SW: Transforming growth factor beta1 prevents IL-1beta-induced microglial activation, whereas TNFalpha- and IL-6-stimulated activation are not antagonized. Glia 2002, 40(1):109-120.